Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Core Insights - Propanc Biopharma, Inc. has received a fourth US patent for its "proenzyme composition," which is crucial for the future clinical dose of its lead asset, PRP [1][2] - The company is advancing to a Phase 1B, First-In-Human study targeting advanced cancer patients with solid tumors, with the global metastatic cancer treatment market projected to reach US$111.2 billion by 2027 [2][3] Company Overview - Propanc Biopharma is focused on developing novel cancer treatments aimed at preventing recurrence and metastasis of solid tumors, specifically targeting pancreatic, ovarian, and colorectal cancers [4][5] - The company's proenzyme therapy leverages pancreatic enzymes, which are believed to stimulate biological reactions and serve as a primary defense against cancer [5] Intellectual Property and Market Strategy - The newly granted patent is part of a broader intellectual property portfolio that includes 90 patents filed in major jurisdictions related to PRP's use against solid tumors [1][2] - The CEO emphasized the importance of the US market for the company's intellectual property growth and highlighted the unique mechanism of PRP as an EMT modulator that induces cancer cell differentiation [3]